863288-34-0
CJC-1295 (no DAC)
Tetra-substituted GHRH(1-29) analogue without the drug affinity complex. Short-acting.
Typical release99.0%
From
£42.00
In stock
Growth Factor & Secretagogue
Tesamorelin
TH9507 · trans-3-hexenoyl-GRF(1-44)
Full-length GHRH(1-44) with an N-terminal hexenoyl group for protease resistance.
Total, ex VAT
£114.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 218949-48-5
- Molecular formula
- C221H366N72O67S
- Average mass
- 5135.9 g/mol
- Residues
- 44
- Class
- N-acylated GHRH(1-44) analogue
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Growth hormone-releasing hormone receptor (GHRHR)
Overview
About Tesamorelin
Tesamorelin is full-length human GHRH(1-44) carrying a trans-3-hexenoyl group on the N-terminal tyrosine. Unlike the 1-29 analogues, it retains the complete native sequence, and the stabilisation comes entirely from the N-terminal acylation rather than from residue substitution.
That design difference is why it is worth holding alongside the shorter analogues. It allows the contribution of the 30-44 region to be tested, and it separates the effect of N-terminal blocking from the effect of internal substitutions such as D-Ala2.
In short
- Full-length GHRH(1-44), not a 1-29 fragment
- Stabilised by N-terminal trans-3-hexenoyl acylation rather than residue substitution
- Allows the contribution of the 30-44 region to be tested
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Sequence contribution
Comparison against 1-29 analogues isolates what the C-terminal region of GHRH contributes to receptor engagement.
Acylation as a stabilisation strategy
Demonstrates N-terminal blocking as an alternative to internal substitution for protease resistance.
Visceral adipose models
The compound has a specific literature in visceral fat distribution that the shorter analogues do not.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of Tesamorelin and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Analogue characterisation
Description of the hexenoyl-modified full-length analogue and its stability relative to native GHRH.
Ferdinandi et al., Basic & Clinical Pharmacology & Toxicology, 2007
Visceral adiposity studies
Clinical work reporting reductions in visceral adipose tissue, which established the compound's distinct profile.
Falutz et al., New England Journal of Medicine, 2007
Questions
Tesamorelin — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- How does it differ from sermorelin?
- Sermorelin is the unmodified 1-29 fragment. Tesamorelin is the full 1-44 sequence with an N-terminal acyl group. Different length, different stabilisation strategy, different mass.
- Is it more difficult to handle?
- It is a longer peptide and slightly more prone to aggregation. Reconstitute gently and avoid agitation.
- What is the typical released purity?
- Around 98.6%. Longer sequences carry more synthesis-related related substances than short peptides, which is reflected in the specification.
Same class
Others in Growth Factor & Secretagogue
170851-70-4
Most orderedIpamorelin
Selective ghrelin receptor agonist pentapeptide with minimal cross-activity.
Typical release99.2%From
£34.00
In stock
86168-78-7
Sermorelin
The native GHRH(1-29) fragment, unmodified. The reference sequence for GHRH analogue work.
Typical release98.8%From
£52.00
In stock
87616-84-0
GHRP-6
First-generation hexapeptide secretagogue at GHS-R1a, with characteristic off-target endocrine activity.
Typical release99.0%From
£29.00
In stock
Important
Tesamorelin is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.